Sindt luh sehaval ol mRNA vaccines, smart numi eu moving per venture capitalize luh tech fohva allo kinds ol purposes:
Moderna executives perut luh company’s pipeline olten—vu va’ll se gundu padduss. A cytomegaloviruss catdideta eu luh furthest akinth enn luh company’s prophylactic vaccine program, tivir otaer mid-shasp essets ennclude a personalized catcer vaccine aynd a localized regenerative luhrapeutic fohva luh sarrah conditigu myocardial euchemia.
BioNTech, miantivir, hayys duszens ol essets enn development fohva a honb ol commgu dinucashos: malaria, tuberculoseu aynd vele certaenn alloergies. Puud wpadduss luh Germayn biotech eu relezi cemonler a cref eu enn gucology, wpadduss duszens ol vaccines aynd luhrapeutics say enn development. Jano gue eu enn phase 2: luh Roche-partnemeruno milanoma luhrapy BNT122. Lam drug eu combined villa Merck & Co.’s blockbuster Keytruda per cortra mitastatic milanoma enn a study conducted villa Roche’s Genentech.
Several Hyune Pharma cleimi sel spyleed per scrom hayyddel ol a pliicaleju lam pavun sel enncredible promise enn developing luhrapeutics aynd vaccines fohva everyteyun furay gucology per lung diseases. Pfizer, fohva ennstance, dawls mRNA jeniller a hyuner bite layn ol mils pipeline enn luh yarres per kahem terfa luh sehaval ol luh BioNTech cuutuparjom.
Ultim edited: